Table 1.
Histopathologic characterization of the 64 patients in training and validation sets
| CHARACTERISTIC | TRAINING SET (N = 92) | VALIDATION SET (N = 29) |
|---|---|---|
| Age | 50 (± 12.6) | 51 (± 12.7) |
| Tumor bed size (mm) | 51.3 (± 35.7) | 84.7 (± 82.2) |
| Hormonal status | No. of patients (%) | |
| ER | 63 (68%) | 19 (65%) |
| PR | 46 (50%) | 17 (57%) |
| HER2 | 58 (63%) | 19 (65%) |
| Grade | No. of patients (%) | |
| 1 | 12 (13%) | 4 (14%) |
| 2 | 49 (53%) | 14 (48%) |
| 3 | 18 (19%) | 11 (38%) |
| N/A | 13 (14%) | 0 |
| Histology | No. of patients (%) | |
| IDC | 65 (71%) | 27 (93%) |
| ILC | 10 (11%) | 2 (7%) |
| Other | 16 (17%) | 0 |
| Clinical response | No. of patients (%) | |
| CPR | 8 (9%) | 0 |
| PDR | 77 (84%) | 27 (93%) |
| NDR | 5 (5%) | 2 (7%) |
| Other | 1 (1%) | 0 |
IDC: intra-ductal carcinoma, ILC: intra-lobular carcinoma, CPR: complete pathological response, PDR: probable or definite response, NDR: no definite response.